Welcome to episode 84 of AI in Action, the podcast that breaks down the hype and explores the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives.
Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts to showcase the excellent work that is being done within AI in the United States and Europe.
Today's guest is Joern Klinger, CEO and Co-Founder at biotx.ai in Berlin. Founded in 2017, biotx.ai delivers predictive biomarkers as a basis for decision support in precision medicine. They use novel, state of the art, machine learning approaches specifically designed to find complex patterns in biomedical data.
biotx.ai has the only AI specifically designed to make wide data manageable. Using graphs of contextual knowledge about metabolic pathways, protein co-expression and protein-protein interactions, they are able to separate the meaningful features from the noise. This allows them to apply all the benefits of big data to wide genomic data.
In the show, Joern will tell you about:
The motivation for setting up Biotx
Developing a new strategy in response to COVID-19
How Biotx stand out from the competition
Challenges they need to overcome within drug discovery
Transitioning from research into a business-focused startup
Interesting use cases of their work in production
New trends and breakthroughs within biomedicine
What did you make of Joern's podcast? Where do you see the future of Artificial Intelligence and Data Science heading in the healthcare sector? We would love to hear your thoughts on this episode, so please leave a comment below.
If you would like to hear more from AI in Action then please subscribe and don’t forget to like and share with your friends on social media.